© 2023 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
After a patient receives a kidney cancer diagnosis, there are some important conversations to have with their health care team.
After receiving a diagnosis of renal cell carcinoma — the most common form of kidney cancer — there are some key facts about the disease and its treatment that patients should discuss with their health care team, according to Dr. Laurence Albiges, a genitourinary medical oncologist from the Gustave Roussy Institute in France.
First and foremost, it is important to know what kind of kidney cancer a patient has, be it clear-cell renal cell carcinoma, the more common subtype where the cancer cells — which appear clear under a microscope — are located in the tubules that filter waste from the blood; or non-clear cell renal cell carcinoma, a rarer type of cancer that may have certain genetic factors at play.
Next, it is important for patients and clinicians to discuss the proper treatment plan, which may include combination of immunotherapy (IO) agents, which use the body’s immune system to find and fight cancer. Patients may also be treated with an IO drug plus a tyrosine kinase inhibitor (TKI), which can block cancer cells from growing and reproducing.
Finally, once a treatment plan is established, patients should know what kind of potential side effects to look out for, Albiges emphasized.
READ MORE: Risk Versus Reward: Managing Side Effects of Kidney Cancer Treatment
So, from a patient standpoint, I think it's important to understand what kind of disease are we facing? Is it a clear cell or what we call a non-clear cell subtypes?
Second, what is the treatment strategy that is being defined? Is the patient going to receive a combination of IO (plus) IO, or is it IO (plus) TKI? And then what is the safety profile or the signals of toxicity that the patient should be aware of, so that it wouldn't delay proper management.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Nubeqa Plus ADT to Be Studied in Prostate Cancer Subset
Educated Patient® Breast Cancer Summit at MBCC De-Escalation of Surgery Presentation: March 4, 2023
Facing My Mortality from Cancer Made Me Grateful for Loved Ones
From Bedside to the Starting Line, a Patient Bonds With Her Oncologist Through Running